Search results for "vaccine."

showing 10 items of 789 documents

β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10

2015

Recent studies have demonstrated that β-catenin in DCs serves as a key mediator in promoting both CD4(+) and CD8(+) T-cell tolerance, although how β-catenin exerts its functions remains incompletely understood. Here we report that activation of β-catenin in DCs inhibits cross-priming of CD8(+) T cells by up-regulating mTOR-dependent IL-10, suggesting blocking β-catenin/mTOR/IL-10 signaling as a viable approach to augment CD8(+) T-cell immunity. However, vaccination of DC-β-catenin(-/-) (CD11c-specific deletion of β-catenin) mice surprisingly failed to protect them against tumor challenge. Further studies revealed that DC-β-catenin(-/-) mice were deficient in generating CD8(+) T-cell immunit…

Mice KnockoutImmunity CellularMultidisciplinaryTOR Serine-Threonine KinasesPriming (immunology)Dendritic CellsBiologyBiological SciencesCD8-Positive T-LymphocytesCancer VaccinesCell biologyInterleukin-10Interleukin 10MiceMediatorImmunityCateninNeoplasmsImmunologyCytotoxic T cellAnimalsPI3K/AKT/mTOR pathwayCD8beta Catenin
researchProduct

Can influenza vaccination coverage among healthcare workers influence the risk of nosocomial influenza-like illness in hospitalized patients?

2013

Background Approximately 20% of healthcare workers are infected with influenza each year, causing nosocomial outbreaks and staff shortages. Despite influenza vaccination of healthcare workers representing the most effective preventive strategy, coverage remains low. Aim To analyse the risk of nosocomial influenza-like illness (NILI) among patients admitted to an acute care hospital in relation to influenza vaccination coverage among healthcare workers. Methods Data collected over seven consecutive influenza seasons (2005–2012) in an Italian acute care hospital were analysed retrospectively. Three different sources of data were used: hospital discharge records; influenza vaccination coverage…

Microbiology (medical)AdultMalemedicine.medical_specialtyAdolescentHealth PersonnelPopulationInfection controlSettore MED/42 - Igiene Generale E ApplicataRisk AssessmentYoung AdultAcute careHealth careInfluenza HumanmedicineInfection controlHumansIntensive care medicineeducationAgedRetrospective StudiesInfluenza-like illnesseducation.field_of_studyCross Infectionbusiness.industryIncidence (epidemiology)VaccinationGeneral MedicineMiddle AgedInfluenza vaccinationVaccinationInfectious DiseasesCross-Sectional StudiesItalyInfluenza VaccinesNosocomial influenzaVaccination coverageEmergency medicineHealthcare workerFemalebusiness
researchProduct

Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza.

2013

Background. In most seasons, the influenza vaccine is effective in preventing influenza, but it is not clear whether it is equally effective in preventing mild and severe cases. We designed a case-control study to compare the effectiveness of the influenza vaccine in preventing outpatient, inpatient, and severe or fatal cases of laboratory-confirmed influenza. Methods. Hospitalized patients (n = 691) with laboratory-confirmed influenza in the 2010–2011 season recruited in 29 Spanish hospitals were individually matched by age, admission/visit date, and province with an outpatient with laboratory-confirmed influenza and an outpatient control. Severe cases were considered those patients admitt…

Microbiology (medical)AdultMalemedicine.medical_specialtyAdolescentInfluenza vaccineLower riskLogistic regressionYoung AdultPregnancyInternal medicineIntensive careInfluenza HumanOutpatientsmedicineHumansIntensive care medicineChildAgedAged 80 and overCross InfectionInpatientsbusiness.industryConfoundingInfant Newbornvirus diseasesInfantOdds ratioMiddle AgedPrognosisConfidence intervalVaccinationCommunity-Acquired InfectionsHospitalizationInfectious DiseasesInfluenza VaccinesSpainCase-Control StudiesChild PreschoolFemalebusinessClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C co…

2007

ABSTRACT We evaluated two formulations of a new combined Haemophilus influenzae type b (Hib)-meningococcal serogroup C (MenC)-tetanus toxoid (TT) conjugated vaccine and two formulations of a new MenC-TT vaccine (trials 711202/001 and 711202/008; clinical trial register numbers NCT00135486 and NCT00135564 [ www.ClinicalTrials.gov ]). A total of 520 healthy infants were randomized to receive primary vaccination (at 2, 3, and 4 months) with either MenC-TT plus diphtheria-tetanus-acellular pertussis (DTPa)-hepatitis B virus (HBV)-inactivated poliovirus (IPV)/Hib, Hib-MenC-TT plus DTPa-HBV-IPV, or MenC-CRM 197 plus DTPa-HBV-IPV/Hib (control). At 12 to 15 months, subjects received a polysaccharid…

Microbiology (medical)Clinical BiochemistryImmunologyPopulationMeningococcal VaccinesMeningococcal vaccineNeisseria meningitidis Serogroup CMeningococcal diseasemedicine.disease_causecomplex mixturesHaemophilus influenzaeAntigen-Antibody ReactionsConjugate vaccineImmunology and AllergyMedicineHumanseducationHaemophilus Vaccineseducation.field_of_studyAntigens BacterialReactogenicityVaccines Conjugatebusiness.industryNeisseria meningitidisInfantmedicine.diseaseVaccine ResearchVirologyAntibodies BacterialHaemophilus influenzaeVaccinationImmunologybusinessImmunologic MemoryClinical and vaccine immunology : CVI
researchProduct

Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles.

2009

ABSTRACTDendritic cells (DCs) internalize and process antigens as well as activate cellular immune responses. The aim of this study was to determine the capacity of DCs that contain antigen-coated magnetic beads to induce immunity against the nonstructural hepatitis C virus (HCV) antigen 5 (NS5). Splenocytes derived from Fms-like tyrosine kinase receptor 3 (Flt3) ligand-pretreated BALB/c mice were incubated with magnetic beads coated with HCV NS5, lipopolysaccharide (LPS), and/or anti-CD40; purified; and used for immunization. Cellular immunity was measured using cytotoxic T-lymphocyte (CTL) and T-cell proliferation assays, intracellular cytokine staining, and a syngeneic tumor challenge us…

Microbiology (medical)Cytotoxicity ImmunologicCellular immunityLipopolysaccharidevirusesT-LymphocytesClinical BiochemistryImmunologychemical and pharmacologic phenomenaHepacivirusBiologyViral Nonstructural Proteinschemistry.chemical_compoundMiceImmune systemAntigenImmunitySplenocyteImmunology and AllergyCytotoxic T cellAnimalsCell ProliferationMice Inbred BALB Cvirus diseasesDendritic CellsCytotoxicity Tests ImmunologicVaccine ResearchMolecular biologyMicrospheresCTL*chemistryCytokinesFemaleClinical and vaccine immunology : CVI
researchProduct

Q fever in Europe: current aspects of aetiology, epidemiology, human infection, diagnosis and therapy.

1987

Il s'agit d'une zoonose. Elle est en general asymptomatique bien que des decouvertes nouvelles aussi bien chez l'homme que chez l'animal mettent en evidence des syndromes cliniques associes en particulier des maladies chroniques graves

Microbiology (medical)Gynecologymedicine.medical_specialtyPathologybusiness.industryQ feverGeneral MedicineInfection diagnosismedicine.diseaseEuropeInfectious DiseasesCoxiellaGeneral practiceEpidemiologyAcute DiseaseBacterial VaccinesChronic DiseasemedicineEtiologyAnimalsHumansbusinessQ FeverInfection
researchProduct

Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concent…

2011

ABSTRACT We compared the abilities of two serological readouts, antipolysaccharide IgG antibody concentrations and opsonophagocytic activity (OPA) titers, to predict the clinical effectiveness of the 7-valent pneumococcal conjugate vaccine (7vCRM) against invasive pneumococcal disease (IPD). We also assessed the accuracy of the previously established thresholds for GlaxoSmithKline's enzyme-linked immunosorbent assay with 22F adsorption (22F-ELISA) (≥0.2 μg/ml) and OPA assay (titer, ≥8) in predicting effectiveness. We showed that following a 3-dose 7vCRM primary vaccination, the serological response rates as determined using thresholds of ≥0.2 μg/ml IgG and an OPA titer of ≥8 corresponded we…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineClinical BiochemistryImmunologyEnzyme-Linked Immunosorbent AssayBiologyPneumococcal conjugate vaccineImmunoglobulin GSerologyPneumococcal VaccinesImmune systemPhagocytosisHeptavalent Pneumococcal Conjugate VaccinemedicineImmunology and AllergyHumansmedicine.diagnostic_testOpsonin ProteinsVaccine ResearchVirologyAntibodies BacterialTiterImmunoassayImmunoglobulin GImmunologybiology.proteinAntibodymedicine.drugClinical and vaccine immunology : CVI
researchProduct

Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate …

2011

Background Induction of immunologic memory was assessed following primary vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Methods Infants were randomized (1:1) to receive 3 doses of PHiD-CV or 7vCRM (7-valent CRM197-conjugated pneumococcal conjugate vaccine [PCV]) at 2, 3, and 4 months of age followed by 23-valent pneumococcal polysaccharide vaccine (23vPS) booster dose at 11 to 14 months of age. Pneumococcal geometric mean antibody concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers were measured. Results Postprimary immune responses were consistent with those in previous PHiD-CV and 7vCRM studies…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesPneumococcal conjugate vaccinePneumococcal InfectionsHaemophilus influenzaePneumococcal VaccinesConjugate vaccinemedicineHeptavalent Pneumococcal Conjugate VaccineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesVaccines Conjugatebusiness.industryVaccinationInfantOpsonin ProteinsPneumococcal polysaccharide vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesStreptococcus pneumoniaeTreatment OutcomeImmunizationPediatrics Perinatology and Child HealthImmunologybusinessImmunologic Memorymedicine.drugThe Pediatric infectious disease journal
researchProduct

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D…

2009

Background The choice of non-typeable Haemophilus influenzae Protein D as main carrier protein in the candidate 10-valent pneumococcal conjugate vaccine (PHiD-CV, GlaxoSmithKline Biologicals), was driven in part to avoid carrier-mediated suppression and possible bystander interference with coadministered vaccines. Immunogenicity data from 3 primary and 2 booster vaccination studies were assessed for possible impacts of PHiD-CV coadministration on immune responses to routinely administered childhood vaccines, in comparison to 7-valent pneumococcal conjugate vaccine (7vCRM) coadministration. Methods Randomized, controlled studies in which PHiD-CV or 7vCRM vaccines were coadministered with DTP…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineLipoproteinsImmunization SecondaryMeningococcal VaccinesBooster dosemedicine.disease_causeAntibodies Viralcomplex mixturesPneumococcal conjugate vaccineHaemophilus influenzaePneumococcal VaccinesBacterial ProteinsConjugate vaccineHeptavalent Pneumococcal Conjugate VaccineMedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicVaccines Conjugatebusiness.industryImmunization ProgramsDiphtheriaImmunogenicityVaccinationInfantImmunoglobulin Dmedicine.diseaseVirologyAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesTreatment OutcomePediatrics Perinatology and Child HealthImmunologybusinessCarrier Proteinsmedicine.drugThe Pediatric infectious disease journal
researchProduct

Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?

2017

International audience

Microbiology (medical)MESH: Antiviral AgentsMESH: Hepatitis B ChronicMEDLINEMESH: Hepatitis B Core AntigensAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicmedicineHumansHepatitis B Vaccines030212 general & internal medicineHepatitis B AntibodiesMESH: Hepatitis B AntibodiesMESH: Hepatitis B VaccinesMESH: Humansbusiness.industryHepatitis Bmedicine.diseaseVirologyHepatitis B Core AntigensHepatitis b core antibodyMESH: DNA ViralInfectious Diseases[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieImmunologyDNA Viral030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct